Dr. Reddy's announces the launch of Desloratadine ODT Dr. Reddy's Laboratories announced that it has launched Desloratadine Orally Disintegrating Tablets, or ODT, a bioequivalent generic version of Clarinex Reditabs in the US market on January 24. Dr. Reddy's ANDA for Desloratadine ODT is approved by the FDA. The Clarinex Reditabs brand had U.S. sales of approximately $5.3M for the most recent twelve months ending November 2012, according to IMS Health.
News For RDY From The Last 14 Days
Check below for free stories on RDY the last two weeks.